Published in Vaccine Weekly, September 27th, 2006
The report was given at the Cambridge Healthtech Institute's 3rd Annual Cancer Immunotherapeutics and Vaccines Conference in Boston, Mass.
Ongoing findings from the two Phase I clinical trials for DCVax-Brain were as follows. Seven of 16 patients are still alive, with follow-up times ranging from 18 to 75 months; six of these seven patients have shown no cancer recurrence.
In a landmark analysis at 24 months, 63% of treated patients were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly